Curis, Inc

Curis is headquartered in the United States and its operating footprint is primarily U.S.-based because its clinical development, financing, and corporate functions are centered there. The company expects future royalty revenue from Erivedge sales in the U.S. and from Roche sales outside the U.S., so its cash flow is linked to both domestic and international commercialization. The filings also note exposure to international trade policy, including China-related supply chain and tariff risk, which matters because clinical development depends on timely access to materials and services. No country-level revenue table was disclosed in the provided excerpts, so the geographic picture is based on narrative disclosure rather than an authoritative revenue split.

Curis faces substantial execution risk because its future depends heavily on the clinical and commercial progress of a single lead asset, emavusertib. The company also disclosed going-concern and liquidity pressure, including the need to raise additional capital and the possibility that it may not regain or maintain Nasdaq listing compliance. Because Curis relies on royalty income from Erivedge and has sold a portion of those future royalties, cash generation is limited and partially encumbered. More broadly, biotechnology development carries high regulatory, trial, manufacturing, and partner-dependency risk, while trade policy, supply chain disruption, and FDA staffing or shutdown issues can delay development timelines.